CSIRO and TRI award grants to fast-track digital healthcare solutions

In Australia, IBD is a significant health concern affecting an estimated 100,000 people, and cases are on the rise. It encompasses two main conditions: Crohn’s disease and ulcerative colitis, both of which involve chronic inflammation of the gastrointestinal tract. Known as anaemia of inflammation, an estimated 30% of IBD sufferers will experience anaemia from their disease. It is also seen in patients who suffer other inflammatory and autoimmune diseases.

Eminent cancer researcher and clinician Professor Maher Gandhi has been appointed as the next Chief Executive Officer of TRI.

A world-first clinical trial for metastatic prostate cancer is underway, using a specialised treatment developed by TRI-based AdvanCell.

Peptides derived from a crab and a spider core to research findings.

TRI has a partnership with The Jackson Laboratory to establish Australia’s first immune-humanised preclinical model generation and distribution facility.

Researchers are determining the feasibility of a clinical trial for a new therapy to help improve the lifespan of people with cystic fibrosis.

TRI-based researchers from QUT are progressing our understanding of the human microbiome and its role in human health and disease.

TRI CEO Professor Scott Bell has been recognised for his outstanding contribution to cystic fibrosis with a prestigious international award.

Researchers based at TRI are developing Parkinson’s disease treatments by targeting the gut microbiome.

Vaxxas has produced its 100th batch of needle‐free vaccine patches at TRI – technology that may soon help protect Australians against infectious diseases.

TRI-based researchers, industry tenants, collaborators and affiliates are sharing in more than $17million in the latest round of National Health and Medical Research Council (NHMRC) funding.

The Translational Research Institute (TRI) has awarded four Translation Fellowships to mid-career researchers.

A radiopharmaceutical company based at TRI is part of a world-first trial of a treatment for difficult-to-treat cancers that have spread in the body.

Respected respiratory physician Professor Scott Bell has announced he will not seek an extension of his five-year tenure as Chief Executive Officer of TRI.

TRI-based researcher Dr Arutha Kulasinghe is combining cancer biology, high-speed imaging, advanced machine learning and artificial intelligence processing power to better understand cancer at a cellular level.

Professor Kum Kum Khanna has joined Mater Research, with the aim of developing new treatments, or repurposing FDA-approved medicines, for treatment of aggressive forms of breast and ovarian cancer.

Mater Research is set to spearhead the development of a ground-breaking vaccine to treat ovarian cancer thanks to a $670,000 OCRF (Ovarian Cancer Research Foundation) grant announced today.

Queensland researchers have become the first in Australia to use human stem cells to generate fully functioning skin tissue in a laboratory, a significant step towards better treatments for severe burns and wounds.

DNA changes consistent with life-threatening pregnancy complications have been found in the placentas of pregnant women infected by COVID-19, according to researchers from The University of Queensland.

Seven projects have secured funding from TRI through the latest LINC grants, to progress research in the areas of cancer, children’s immunity and blood infection.

Immunologist Dr Jazmina Gonzalez Cruz is leading a pioneering research program to identify and design personalised cancer treatments.

TRI-based researchers from The University of Queensland, Mater Research and Queensland University of Technology are sharing in more than $12million in the latest round of National Health and Medical Research Council (NHMRC) funding.

TRI-based researchers from The University of Queensland, Mater Research and Queensland University of Technology are sharing in more than $12million in the latest round of National Health and Medical Research Council (NHMRC) funding.

Mater Researcher Professor John Hooper will share in $1.8 million of funding from PanKind, the Australian Pancreatic Cancer Foundation, to investigate early detection and new treatments for pancreatic cancer.

TRI is home to the new Mater Research Musculoskeletal Genomics Group, with its focus firmly on discovering new therapeutic targets for musculoskeletal disorders.

Paying tribute to philanthropist Charles ‘Chuck’ Feeney, who was instrumental in supporting the establishment of major research institutes around South East Queensland – including TRI.

QUT Professor in Breast Cancer Research Rik Thompson leads a TRI-based group aiming to understand the molecular and cellular processes driving breast cancer risk, progression and therapy resistance.

Researchers from The University of Queensland and The Alfred hospital in Melbourne have identified gene variants which may contribute to people being at higher risk for nodular melanoma.

TRI-based Mater Researchers have discovered that an immune factor released by white blood cells during infection or inflammation works to suppress the body’s immune response instead of enhancing it.

The University of Queensland researchers have identified a novel drug target with the potential to overcome drug resistance and prevent tumour regrowth in cancer patients.

Patient recruitment is underway for a University of Queensland-led clinical trial to test the effectiveness of a diabetes drug to slow the progression of polycystic kidney disease.

Researchers at TRI are helping scientists and industry develop the most effective formulations and methods for delivering therapeutics via the skin.

TRI-based researcher Dr Joshua Tobin, a member of Mater Research’s Blood Cancer Group led by Professor Maher Gandhi, has recently been awarded $150,000 in funding to further his research into lymphoma.

TRI-based scientists from Mater Research and The University of Queensland have recently identified a potential treatment to enhance the healing of fractures among osteoporosis sufferers.

Researchers from The University of Queensland have supported a study to improve the performance of an artificial intelligence (AI) model in skin cancer diagnosis and management.

Professor Jo Forbes from Mater Research says Type 1 diabetes in children is twice as common now than it was 20 years ago.

TRI has awarded four Translation Fellowships to early and mid-career researchers. The 12-month Fellowships, valued at $20,000 each, were launched in 2023 as part of TRI’s flagship Translation Pathways program.

TRI and its hospital partners have jointly awarded new research grants to drive new collaborations between clinicians and scientists.

TRI and the Australia e-Health Research Centre at CSIRO have jointly awarded $300,000 to innovative projects aimed at solving a healthcare challenge.

The first patient of an ongoing clinical trial has recovered well following world-first sutureless nerve repair surgery.

A new study has identified that fat molecules contribute to sleep disturbances in children diagnosed with autism, with results now published in Nature Medicine.

Liver damage could be a major outcome of severe COVID-19 infection in a landmark study involving TRI-based researchers.

QUT scientists at the Translational Research Institute (TRI) are harnessing a new class of pharmaceutical compounds, known as aptamers, to develop a drug to boost the immune system’s ability to fight cancer.

A microorganism that helps reduce the release of the greenhouse gas methane into the atmosphere has been found to be a ‘shape shifter’.

Australian women could better gauge their breast cancer risk through new imaging technology, without radiation that comes with mammography.

TRI has marked 10 years since the first staff from research partners The University of Queensland, QUT, Mater Research and Metro South Health began to move into the building.

The possibility of a mouthwash or nasal spray to prevent or reduce the spread of the COVID-19 infections is being investigated by TRI-based QUT scientists.

QUT researchers based at TRI are developing new drugs to shut down the energy pathways essential to prostate cancer cells’ survival.

TRI CEO Professor Scott Bell has contributed to a CSIRO report that sets out how Australia can improve its resilience to future pandemics.

A medical manufacturing facility, equipped to produce promising drugs and vaccines for clinical trials, will be built with $60 million from the Queensland Government.

TRI, Metro South Health and Mater Research have announced the recipients of almost $400,000 in research grant funding through their jointly funded LINC scheme.

Researchers have unlocked a way of fighting listeria infections, which can cause severe illness in pregnancy and people with compromised immune systems.

Anti-androgen therapy used to treat patients with advanced prostate cancer may be fuelling bone cancer spread.

Children who consume too much sugar could be at greater risk of becoming obese, hyperactive and cognitively impaired as adults, a study has found.

The world-first treatment being developed by TRI-based researchers from The University of Queensland is the only drug of its type that could prevent the incidence of skin cancers for transplant patients.

Researchers have found that lanthanum carbonate does not reduce the risk of cardiovascular disease developing in patients with chronic kidney disease.

TRI-based researchers from The University of Queensland have unlocked a way of fighting Listeria infections, which can cause severe illness in pregnant women and people with compromised immune systems.

Scientists have discovered they can overcome chemotherapy resistance in an ovarian cancer subtype by using low doses of a drug which slows cell growth.

Scientists from Mater Research have discovered they can overcome chemotherapy resistance in an ovarian cancer subtype by using low doses of a drug which slows cell growth.

A drug used to treat high blood pressure may alleviate anxiety induced by long-term heavy alcohol use, and also halt the damage such drinking can cause to the brain’s ability to grow new cells, QUT researchers based at TRI have found.

A new spin-out from The University of Queensland will develop a novel therapy for the growing problem of obesity-related liver disease.

QUT scientist recognised for outstanding research and academic achievement, as well as excellence in communication and community engagement.

Research in the Journal of Clinical Oncology has reported findings that may inform treatment and improve outcomes for patients with follicular lymphoma.

Professor H. Peter Soyer has been awarded $10 million for the Australian Centre of Excellence in Melanoma Imaging and Diagnosis at TRI.